Nucleix will announce new clinical results and latest developments in their booth
Rehovot, Israel, March 16th 2017 - Nucleix, an innovative cancer detection and screening company, announced today that it will exhibit its Bladder EpiCheck in the next annual meeting of the EAU in London on March 25th – 27th.
Bladder EpiCheck, Nucleix’s first product, is an IVD test for bladder cancer monitoring in urine samples. It includes 15 methylation biomarkers that are multiplexed together to achieve better performance – sensitivity, specificity and negative predictive value (NPV).
“We are proud to present our latest data at the EAU, one of the largest urology meetings in the world” said Elon Ganor, Nucleix’s Co-founder and Chief Executive Officer. “With its excellent performance and objectivity, Bladder EpiCheck will further help urologists to improve their patients’ bladder cancer monitoring”
Nucleix will exhibit at booth A-07 in the main exhibition hall.
About Nucleix - Nucleix Ltd. develops, manufactures and markets innovative non-invasive molecular cancer diagnostic tests. Its highly sensitive and specific tests are based on identification of subtle changes in methylation patterns. Nucleix technology is based on a combination of a new biochemical platform in conjunction with sophisticated algorithms.
Our first product Bladder EpiCheck is a urine test for monitoring of bladder cancer, and includes a panel of 15 proprietary biomarkers that are multiplexed in a real-time PCR analysis.
Nucleix pipeline includes a diagnostic test for lung cancer screening from blood samples, using its proprietary and highly innovative technology.
Nucleix is backed up by leading investors including OrbiMed - the world’s largest bio-medical VC fund.
Contact Nucleix at: info@nucleix.com
Nucleix Website: www.nucleix.com
